SpringWorks Therapeutics and the ReNeu Trial for NF1-Related Plexiform Neurofibromas

SpringWorks is a biopharmaceutical company whose mission is to develop life-changing medicines for patients with severe rare diseases and cancer. They are conducting a Phase 2b clinical trial (the “ReNeu trial”) with their investigational MEK inhibitor called mirdametinib in children and adults with NF1-associated plexiform neurofibromas (NF1-PN). During the webinar, people will learn about the differences between NF1 and NF2, what plexiform neurofibromas are, and more about mirdametinib and the ReNeu trial. Speakers include Dr. Mary Smith, Chief Development Officer of SpringWorks and members of her team who are responsible for helping to conduct the ReNeu trial.